Trial reportBMC medicine2025
Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vaccine safety for individuals receiving immune checkpoint inhibitor therapy: A narrative review of current literature and recommendations for future research.Human vaccines & immunotherapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundCamrelizumab (an anti-programmed cell death protein-1 antibody) combined with apatinib (an antiangiogenic agent) has conferred benefits for advanced NSCLC. This study aimed to assess the efficacy and safety of camrelizumab and apatinib alongside chemotherapy in patients with resectable stage IIIA (N2) NSCLC as neoadjuvant therapy.
methodsPatients with stage IIIA (N2) NSCLC were treated with a combination of chemotherapy, camrelizumab (200 mg, once every 3 weeks [q3w]), and apatinib (250 mg, once daily). Surgery was planned after 2-4 cycles of therapy. The primary endpoint was major pathological response (MPR) rate, with secondary endpoints including pathological complete response (pCR) rate, R0 resection rate, objective response rate (ORR), and safety. The trial was registered at ChiCTR.org.cn (ChiCTR2200059608).
resultsThirty-one patients were enrolled from August 4, 2021, to October 8, 2023. The disease control rate (DCR) was 93.5%, while the ORR was 87.1% and a clinical down-staging rate of 19.4%. Among them, 20 patients underwent complete resection, the MPR rate was 65.0%, and the pCR rate was 40%. Any grade neoadjuvant adverse events (AEs) were reported in 31 (100%) of the patients, and grade 3/4 AEs in 19 (61.3%). The most common AEs of any grade were fatigue (61.3%), nausea (54.8%), and decreased white blood cell count (51.6%). These conditions typically return to normal within a short period following observation or pharmacological treatment. No treatment-related deaths occurred.
conclusionsThe synergistic application of chemotherapy with camrelizumab and apatinib showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a promising therapeutic alternative for individuals with resectable stage IIIA (N2) NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.